BioWorld Asia

April 27, 2005

TKT Absorbed For $1.6B As Shire Fattens Pipeline

In what could be the largest acquisition of 2005 - and certainly the largest so far - Shire Pharmaceuticals Group plc has nabbed Transkaryotic Therapies Inc. in a deal worth $1.6 billion. (BioWorld International) Read More

£32.8M For Alizyme Earmarked For Renzapride, Cetilistat Work

Blocking Toxins Could Defeat Bacterial Antibiotic Resistance

Genmab Moves Zanolimumab Into Lymphoma Pivotal Study

Tight Agrobiotech Rulings Provoke German Lawsuit

Cash Squeeze Could Hamper Finnish Personalized Medicine

Microdosing Guidelines From FDA Might Reduce Time, Waste

Europe Pressures Syngenta On Testing, Containing Bt10

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 31, 2026.

Illustration of dopamine signaling in the brain

New schizophrenia targets challenge trial design

BioWorld

The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 28, 2026

AIDS 2026: New targets for metabolic dysfunction despite ART

BioWorld

Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...

Fauci’s silence may put him in contempt of Congress

BioWorld

After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...